Jennifer Michele Manne-Goehler, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Chagas Disease | 14 | 2022 | 164 | 3.910 |
Why?
|
Diabetes Mellitus | 31 | 2024 | 5840 | 2.840 |
Why?
|
Developing Countries | 27 | 2024 | 2820 | 2.760 |
Why?
|
Rural Population | 26 | 2024 | 2239 | 2.530 |
Why?
|
HIV Infections | 32 | 2024 | 17006 | 2.170 |
Why?
|
South Africa | 25 | 2024 | 1773 | 2.130 |
Why?
|
Career Mobility | 2 | 2020 | 257 | 1.230 |
Why?
|
Trypanocidal Agents | 4 | 2020 | 40 | 1.200 |
Why?
|
Hypertension | 19 | 2024 | 8497 | 1.200 |
Why?
|
Nitroimidazoles | 4 | 2020 | 112 | 1.120 |
Why?
|
Triatoma | 2 | 2018 | 10 | 1.060 |
Why?
|
Insect Control | 2 | 2018 | 27 | 1.040 |
Why?
|
Oxazines | 2 | 2024 | 323 | 1.010 |
Why?
|
Insect Vectors | 2 | 2018 | 130 | 0.980 |
Why?
|
Heterocyclic Compounds, 3-Ring | 2 | 2024 | 262 | 0.970 |
Why?
|
Income | 11 | 2023 | 1864 | 0.950 |
Why?
|
Weight Gain | 2 | 2024 | 2329 | 0.910 |
Why?
|
Faculty, Medical | 3 | 2020 | 1178 | 0.900 |
Why?
|
Antiretroviral Therapy, Highly Active | 4 | 2020 | 1898 | 0.840 |
Why?
|
Poverty | 12 | 2024 | 2638 | 0.830 |
Why?
|
Pyridones | 2 | 2024 | 766 | 0.810 |
Why?
|
Cross-Sectional Studies | 44 | 2024 | 25540 | 0.790 |
Why?
|
Health Surveys | 9 | 2022 | 4014 | 0.780 |
Why?
|
Body Mass Index | 6 | 2023 | 12794 | 0.730 |
Why?
|
Blood Pressure | 11 | 2024 | 8468 | 0.730 |
Why?
|
Prevalence | 28 | 2024 | 15505 | 0.710 |
Why?
|
Infectious Disease Medicine | 1 | 2020 | 49 | 0.710 |
Why?
|
Cardiovascular Diseases | 19 | 2024 | 15619 | 0.670 |
Why?
|
Insecticides | 2 | 2018 | 187 | 0.660 |
Why?
|
Health Services Accessibility | 11 | 2024 | 5280 | 0.650 |
Why?
|
Trypanosoma cruzi | 5 | 2022 | 199 | 0.640 |
Why?
|
Nifurtimox | 2 | 2015 | 14 | 0.620 |
Why?
|
Diabetes Mellitus, Type 2 | 8 | 2023 | 12154 | 0.590 |
Why?
|
Delivery of Health Care | 5 | 2020 | 5277 | 0.580 |
Why?
|
Social Stigma | 2 | 2024 | 720 | 0.570 |
Why?
|
National Health Programs | 1 | 2020 | 443 | 0.570 |
Why?
|
Piperazines | 2 | 2024 | 2487 | 0.560 |
Why?
|
Viral Load | 6 | 2024 | 3297 | 0.550 |
Why?
|
Blood Donors | 2 | 2016 | 343 | 0.550 |
Why?
|
Longitudinal Studies | 15 | 2024 | 14323 | 0.540 |
Why?
|
Obesity | 9 | 2024 | 12802 | 0.520 |
Why?
|
Self Report | 6 | 2023 | 3649 | 0.510 |
Why?
|
Adult | 65 | 2024 | 217168 | 0.500 |
Why?
|
Anti-Retroviral Agents | 5 | 2020 | 1771 | 0.490 |
Why?
|
Sex Factors | 8 | 2021 | 10454 | 0.480 |
Why?
|
Comorbidity | 7 | 2020 | 10475 | 0.480 |
Why?
|
Self Concept | 1 | 2020 | 1024 | 0.480 |
Why?
|
Humans | 119 | 2024 | 752810 | 0.470 |
Why?
|
Communicable Diseases | 2 | 2020 | 871 | 0.470 |
Why?
|
Drugs, Investigational | 2 | 2020 | 213 | 0.470 |
Why?
|
Cause of Death | 3 | 2022 | 3685 | 0.470 |
Why?
|
Health Services Needs and Demand | 2 | 2019 | 1392 | 0.450 |
Why?
|
Rural Health Services | 1 | 2017 | 379 | 0.450 |
Why?
|
Cost of Illness | 3 | 2021 | 1911 | 0.450 |
Why?
|
Male | 70 | 2024 | 355160 | 0.450 |
Why?
|
Antiprotozoal Agents | 1 | 2013 | 86 | 0.440 |
Why?
|
Female | 72 | 2024 | 386339 | 0.440 |
Why?
|
Middle Aged | 59 | 2024 | 217250 | 0.440 |
Why?
|
Parturition | 1 | 2017 | 440 | 0.440 |
Why?
|
Disabled Persons | 1 | 2023 | 1214 | 0.430 |
Why?
|
Rhodnius | 1 | 2012 | 4 | 0.420 |
Why?
|
Mexico | 7 | 2024 | 740 | 0.410 |
Why?
|
Medicine | 2 | 2020 | 931 | 0.410 |
Why?
|
Educational Status | 1 | 2020 | 2498 | 0.410 |
Why?
|
Anti-HIV Agents | 6 | 2024 | 4443 | 0.370 |
Why?
|
Primary Prevention | 2 | 2024 | 1183 | 0.370 |
Why?
|
Lamivudine | 2 | 2024 | 350 | 0.360 |
Why?
|
Circumcision, Male | 1 | 2011 | 148 | 0.360 |
Why?
|
Antihypertensive Agents | 4 | 2021 | 2037 | 0.360 |
Why?
|
Patient Acceptance of Health Care | 3 | 2020 | 3117 | 0.350 |
Why?
|
Academic Medical Centers | 1 | 2020 | 2714 | 0.350 |
Why?
|
Uganda | 4 | 2024 | 1308 | 0.340 |
Why?
|
Africa South of the Sahara | 5 | 2023 | 728 | 0.330 |
Why?
|
Socioeconomic Factors | 11 | 2024 | 7746 | 0.330 |
Why?
|
Achievement | 2 | 2020 | 289 | 0.320 |
Why?
|
Blood Glucose | 7 | 2023 | 6332 | 0.310 |
Why?
|
Intensive Care Units | 2 | 2020 | 3699 | 0.300 |
Why?
|
Aged | 40 | 2024 | 166705 | 0.290 |
Why?
|
Financing, Government | 1 | 2010 | 466 | 0.280 |
Why?
|
India | 7 | 2022 | 2282 | 0.280 |
Why?
|
Infectious Disease Transmission, Vertical | 2 | 2022 | 1337 | 0.270 |
Why?
|
Mass Screening | 5 | 2022 | 5395 | 0.270 |
Why?
|
Hypercholesterolemia | 2 | 2023 | 1155 | 0.260 |
Why?
|
Health Services Research | 2 | 2018 | 1809 | 0.250 |
Why?
|
AIDS Vaccines | 1 | 2011 | 892 | 0.250 |
Why?
|
Health Services | 1 | 2010 | 751 | 0.250 |
Why?
|
Epidemics | 2 | 2024 | 508 | 0.250 |
Why?
|
Longevity | 2 | 2023 | 1034 | 0.250 |
Why?
|
Young Adult | 19 | 2024 | 57732 | 0.240 |
Why?
|
Risk Factors | 26 | 2024 | 73418 | 0.240 |
Why?
|
Diabetes Complications | 3 | 2021 | 1341 | 0.230 |
Why?
|
Urban Population | 3 | 2022 | 2006 | 0.230 |
Why?
|
Developed Countries | 3 | 2023 | 440 | 0.220 |
Why?
|
Body Height | 2 | 2020 | 1563 | 0.220 |
Why?
|
Tuberculosis | 3 | 2024 | 1986 | 0.220 |
Why?
|
Metabolic Diseases | 2 | 2022 | 685 | 0.210 |
Why?
|
Women | 2 | 2021 | 226 | 0.200 |
Why?
|
HIV Integrase Inhibitors | 1 | 2024 | 164 | 0.200 |
Why?
|
Alanine | 1 | 2024 | 584 | 0.200 |
Why?
|
Aspirin | 2 | 2024 | 3339 | 0.190 |
Why?
|
Tobacco, Smokeless | 1 | 2022 | 130 | 0.190 |
Why?
|
Cohort Studies | 9 | 2024 | 40996 | 0.190 |
Why?
|
Leadership | 2 | 2021 | 1355 | 0.190 |
Why?
|
Zambia | 1 | 2022 | 255 | 0.190 |
Why?
|
Drug Substitution | 1 | 2024 | 287 | 0.190 |
Why?
|
Anti-Obesity Agents | 1 | 2024 | 221 | 0.190 |
Why?
|
Housing | 2 | 2018 | 656 | 0.190 |
Why?
|
United States | 12 | 2023 | 71434 | 0.180 |
Why?
|
Latin America | 2 | 2022 | 402 | 0.170 |
Why?
|
Emigration and Immigration | 1 | 2022 | 394 | 0.170 |
Why?
|
Adolescent | 18 | 2024 | 86822 | 0.170 |
Why?
|
Program Evaluation | 2 | 2018 | 2464 | 0.170 |
Why?
|
Economic Development | 1 | 2019 | 69 | 0.160 |
Why?
|
Quinolines | 1 | 2024 | 748 | 0.160 |
Why?
|
Nicaragua | 1 | 2018 | 29 | 0.160 |
Why?
|
Diabetes Mellitus, Type 1 | 2 | 2023 | 3375 | 0.150 |
Why?
|
Life Expectancy | 2 | 2023 | 1243 | 0.150 |
Why?
|
Hypotension, Orthostatic | 1 | 2021 | 254 | 0.150 |
Why?
|
Secondary Prevention | 2 | 2023 | 1546 | 0.150 |
Why?
|
Population Density | 1 | 2018 | 192 | 0.150 |
Why?
|
Burkina Faso | 3 | 2024 | 86 | 0.150 |
Why?
|
Health Expenditures | 1 | 2010 | 2334 | 0.150 |
Why?
|
Malnutrition | 1 | 2024 | 635 | 0.150 |
Why?
|
Cytomegalovirus Infections | 1 | 2024 | 829 | 0.150 |
Why?
|
Case Management | 1 | 2019 | 273 | 0.150 |
Why?
|
Social Class | 3 | 2022 | 1992 | 0.150 |
Why?
|
Population Surveillance | 2 | 2018 | 2598 | 0.140 |
Why?
|
Depression | 3 | 2024 | 7920 | 0.140 |
Why?
|
Posture | 1 | 2021 | 952 | 0.140 |
Why?
|
Los Angeles | 1 | 2017 | 240 | 0.140 |
Why?
|
Fibrin Fibrinogen Degradation Products | 1 | 2018 | 419 | 0.140 |
Why?
|
Interviews as Topic | 4 | 2019 | 2619 | 0.140 |
Why?
|
Sexual Partners | 1 | 2021 | 745 | 0.130 |
Why?
|
Glomerular Filtration Rate | 1 | 2024 | 2093 | 0.130 |
Why?
|
Endemic Diseases | 1 | 2016 | 186 | 0.130 |
Why?
|
Cultural Diversity | 1 | 2019 | 350 | 0.130 |
Why?
|
Texas | 1 | 2016 | 397 | 0.130 |
Why?
|
Florida | 1 | 2016 | 419 | 0.130 |
Why?
|
Prospective Studies | 4 | 2024 | 53833 | 0.120 |
Why?
|
Risk-Taking | 1 | 2021 | 988 | 0.120 |
Why?
|
Fitness Centers | 1 | 2014 | 13 | 0.120 |
Why?
|
Focus Groups | 1 | 2020 | 1361 | 0.120 |
Why?
|
Lymphoma, Non-Hodgkin | 1 | 2022 | 1377 | 0.120 |
Why?
|
Overweight | 2 | 2023 | 2400 | 0.120 |
Why?
|
Government Programs | 1 | 2017 | 279 | 0.120 |
Why?
|
Health Policy | 2 | 2017 | 2655 | 0.120 |
Why?
|
Referral and Consultation | 3 | 2021 | 3560 | 0.120 |
Why?
|
Aging | 4 | 2021 | 8573 | 0.120 |
Why?
|
Systems Analysis | 1 | 2015 | 168 | 0.120 |
Why?
|
Health Care Costs | 2 | 2018 | 3209 | 0.120 |
Why?
|
New York | 1 | 2016 | 872 | 0.120 |
Why?
|
Growth Disorders | 1 | 2019 | 626 | 0.120 |
Why?
|
Health | 1 | 2017 | 394 | 0.110 |
Why?
|
Fruit | 1 | 2019 | 1160 | 0.110 |
Why?
|
Vegetables | 1 | 2019 | 1196 | 0.110 |
Why?
|
Epidemiologic Research Design | 1 | 2017 | 365 | 0.110 |
Why?
|
Disease Vectors | 1 | 2013 | 61 | 0.110 |
Why?
|
Schools, Medical | 1 | 2020 | 874 | 0.110 |
Why?
|
Chronic Disease | 2 | 2020 | 9174 | 0.110 |
Why?
|
Indonesia | 2 | 2024 | 124 | 0.100 |
Why?
|
California | 1 | 2016 | 1395 | 0.100 |
Why?
|
HIV Antibodies | 1 | 2019 | 1294 | 0.100 |
Why?
|
Echocardiography, Stress | 1 | 2013 | 135 | 0.100 |
Why?
|
Pyrethrins | 1 | 2012 | 44 | 0.100 |
Why?
|
Weight Loss | 1 | 2023 | 2649 | 0.100 |
Why?
|
Cholesterol | 1 | 2021 | 2903 | 0.100 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2022 | 3307 | 0.100 |
Why?
|
Logistic Models | 2 | 2020 | 13277 | 0.100 |
Why?
|
Parasitic Diseases | 1 | 2012 | 76 | 0.100 |
Why?
|
Guatemala | 1 | 2012 | 156 | 0.100 |
Why?
|
Alcohol Drinking | 2 | 2022 | 3991 | 0.100 |
Why?
|
Diet | 2 | 2020 | 7950 | 0.100 |
Why?
|
Continuity of Patient Care | 1 | 2018 | 1050 | 0.100 |
Why?
|
Sexual Behavior | 1 | 2021 | 2062 | 0.090 |
Why?
|
Sex Characteristics | 2 | 2020 | 2614 | 0.090 |
Why?
|
Incidence | 5 | 2024 | 21162 | 0.090 |
Why?
|
Hyperglycemia | 1 | 2019 | 1373 | 0.090 |
Why?
|
Urban Health | 1 | 2013 | 533 | 0.090 |
Why?
|
Emigrants and Immigrants | 1 | 2016 | 533 | 0.090 |
Why?
|
Decision Support Techniques | 2 | 2011 | 1970 | 0.090 |
Why?
|
Fasting | 3 | 2021 | 1591 | 0.080 |
Why?
|
Decision Support Systems, Clinical | 1 | 2018 | 1147 | 0.080 |
Why?
|
Respiration, Artificial | 1 | 2020 | 2598 | 0.080 |
Why?
|
Glucose | 1 | 2021 | 4354 | 0.080 |
Why?
|
HIV Seronegativity | 2 | 2020 | 207 | 0.080 |
Why?
|
Pregnancy | 2 | 2023 | 29427 | 0.080 |
Why?
|
Quality Assurance, Health Care | 1 | 2019 | 2171 | 0.080 |
Why?
|
Sensitivity and Specificity | 3 | 2019 | 14601 | 0.080 |
Why?
|
Uterine Cervical Neoplasms | 1 | 2020 | 1992 | 0.080 |
Why?
|
Research | 1 | 2017 | 1962 | 0.080 |
Why?
|
Aged, 80 and over | 7 | 2024 | 58347 | 0.080 |
Why?
|
Odds Ratio | 1 | 2020 | 9701 | 0.080 |
Why?
|
Body Weights and Measures | 2 | 2019 | 208 | 0.070 |
Why?
|
Hospitals | 1 | 2021 | 3915 | 0.070 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2024 | 10200 | 0.070 |
Why?
|
China | 2 | 2024 | 2335 | 0.070 |
Why?
|
Health Personnel | 1 | 2020 | 3270 | 0.070 |
Why?
|
Early Detection of Cancer | 1 | 2020 | 3163 | 0.070 |
Why?
|
Environmental Monitoring | 1 | 2012 | 1421 | 0.060 |
Why?
|
Quality of Health Care | 1 | 2020 | 4343 | 0.060 |
Why?
|
Models, Theoretical | 2 | 2021 | 3549 | 0.060 |
Why?
|
Pulmonary Embolism | 1 | 2018 | 2515 | 0.060 |
Why?
|
Severity of Illness Index | 3 | 2019 | 15695 | 0.060 |
Why?
|
Insurance, Health | 1 | 2017 | 2490 | 0.060 |
Why?
|
Hematopoietic Stem Cell Transplantation | 1 | 2022 | 5592 | 0.060 |
Why?
|
International Cooperation | 1 | 2010 | 1421 | 0.060 |
Why?
|
Chile | 1 | 2024 | 246 | 0.060 |
Why?
|
Quality of Life | 3 | 2021 | 13162 | 0.060 |
Why?
|
Exercise | 2 | 2023 | 5745 | 0.050 |
Why?
|
Cognition | 1 | 2020 | 6862 | 0.050 |
Why?
|
C-Reactive Protein | 2 | 2017 | 3805 | 0.050 |
Why?
|
Age Distribution | 2 | 2019 | 2882 | 0.050 |
Why?
|
Health Care Surveys | 2 | 2020 | 2427 | 0.050 |
Why?
|
Neglected Diseases | 1 | 2022 | 65 | 0.050 |
Why?
|
Coronary Artery Disease | 2 | 2013 | 6591 | 0.050 |
Why?
|
Diagnostic Techniques and Procedures | 1 | 2023 | 217 | 0.050 |
Why?
|
HIV-1 | 1 | 2019 | 6827 | 0.050 |
Why?
|
Age Factors | 4 | 2021 | 18302 | 0.050 |
Why?
|
Coronary Angiography | 1 | 2013 | 4543 | 0.050 |
Why?
|
Review Literature as Topic | 1 | 2023 | 333 | 0.050 |
Why?
|
Sex Ratio | 1 | 2021 | 106 | 0.050 |
Why?
|
Smoking | 3 | 2024 | 9029 | 0.050 |
Why?
|
Quality-Adjusted Life Years | 3 | 2013 | 1708 | 0.050 |
Why?
|
Saint Vincent and the Grenadines | 1 | 2020 | 2 | 0.050 |
Why?
|
Brazil | 1 | 2024 | 1185 | 0.040 |
Why?
|
Guyana | 1 | 2020 | 16 | 0.040 |
Why?
|
Serologic Tests | 1 | 2022 | 381 | 0.040 |
Why?
|
Bhutan | 1 | 2020 | 62 | 0.040 |
Why?
|
Georgia | 1 | 2020 | 186 | 0.040 |
Why?
|
Electrocardiography | 1 | 2013 | 6379 | 0.040 |
Why?
|
Antigens, CD19 | 1 | 2022 | 414 | 0.040 |
Why?
|
Cytomegalovirus | 1 | 2024 | 756 | 0.040 |
Why?
|
Health Systems Plans | 1 | 2019 | 19 | 0.040 |
Why?
|
Clinical Competence | 1 | 2015 | 4713 | 0.040 |
Why?
|
Namibia | 1 | 2019 | 26 | 0.040 |
Why?
|
Regression Analysis | 2 | 2019 | 6363 | 0.040 |
Why?
|
Muscles | 1 | 2024 | 1579 | 0.040 |
Why?
|
Frail Elderly | 1 | 2024 | 731 | 0.040 |
Why?
|
Nepal | 1 | 2020 | 299 | 0.040 |
Why?
|
Disease Progression | 4 | 2024 | 13403 | 0.040 |
Why?
|
Prognosis | 3 | 2024 | 29369 | 0.040 |
Why?
|
Cell Count | 1 | 2022 | 1834 | 0.040 |
Why?
|
Comparative Effectiveness Research | 1 | 2023 | 704 | 0.040 |
Why?
|
Meta-Analysis as Topic | 1 | 2023 | 1364 | 0.040 |
Why?
|
Antifungal Agents | 1 | 2022 | 709 | 0.040 |
Why?
|
Radiography, Thoracic | 1 | 2024 | 1287 | 0.040 |
Why?
|
Tuberculosis, Pulmonary | 1 | 2024 | 820 | 0.040 |
Why?
|
Blood Chemical Analysis | 1 | 2019 | 433 | 0.040 |
Why?
|
Markov Chains | 2 | 2013 | 968 | 0.040 |
Why?
|
Kenya | 1 | 2020 | 720 | 0.040 |
Why?
|
World Health Organization | 1 | 2023 | 1293 | 0.040 |
Why?
|
Cardiovascular Agents | 1 | 2023 | 866 | 0.040 |
Why?
|
Blood | 1 | 2019 | 584 | 0.040 |
Why?
|
Colombia | 1 | 2017 | 271 | 0.030 |
Why?
|
Geography | 1 | 2018 | 659 | 0.030 |
Why?
|
Research Personnel | 1 | 2021 | 580 | 0.030 |
Why?
|
Europe | 1 | 2022 | 3407 | 0.030 |
Why?
|
Waist-Hip Ratio | 1 | 2017 | 515 | 0.030 |
Why?
|
Heart Failure | 2 | 2011 | 11728 | 0.030 |
Why?
|
Risk Assessment | 3 | 2021 | 23785 | 0.030 |
Why?
|
HIV Seropositivity | 1 | 2020 | 957 | 0.030 |
Why?
|
Animals | 3 | 2018 | 166825 | 0.030 |
Why?
|
Editorial Policies | 1 | 2019 | 457 | 0.030 |
Why?
|
Specialization | 1 | 2019 | 768 | 0.030 |
Why?
|
Guidelines as Topic | 1 | 2021 | 1389 | 0.030 |
Why?
|
Cost-Benefit Analysis | 3 | 2013 | 5481 | 0.030 |
Why?
|
Retrospective Studies | 4 | 2024 | 79160 | 0.030 |
Why?
|
Sex Distribution | 1 | 2019 | 2290 | 0.030 |
Why?
|
Propensity Score | 1 | 2021 | 1872 | 0.030 |
Why?
|
Gender Identity | 1 | 2019 | 694 | 0.030 |
Why?
|
Forecasting | 1 | 2022 | 2917 | 0.030 |
Why?
|
Radiography | 1 | 2024 | 6964 | 0.030 |
Why?
|
Observer Variation | 1 | 2019 | 2581 | 0.030 |
Why?
|
Antibodies, Viral | 1 | 2024 | 3107 | 0.030 |
Why?
|
Immunotherapy, Adoptive | 1 | 2022 | 1419 | 0.030 |
Why?
|
Medication Adherence | 1 | 2024 | 2133 | 0.030 |
Why?
|
Costs and Cost Analysis | 1 | 2018 | 1674 | 0.030 |
Why?
|
Minority Groups | 1 | 2019 | 1194 | 0.030 |
Why?
|
Immunoglobulin G | 1 | 2024 | 4520 | 0.030 |
Why?
|
Drug Costs | 1 | 2020 | 1176 | 0.030 |
Why?
|
United States Food and Drug Administration | 1 | 2020 | 1665 | 0.020 |
Why?
|
Disclosure | 1 | 2017 | 739 | 0.020 |
Why?
|
Mothers | 1 | 2022 | 2174 | 0.020 |
Why?
|
Child | 3 | 2024 | 78996 | 0.020 |
Why?
|
Mortality | 1 | 2022 | 2881 | 0.020 |
Why?
|
Platelet Aggregation Inhibitors | 1 | 2024 | 3159 | 0.020 |
Why?
|
Predictive Value of Tests | 2 | 2021 | 15146 | 0.020 |
Why?
|
Ambulatory Care | 1 | 2021 | 2743 | 0.020 |
Why?
|
Peru | 1 | 2013 | 859 | 0.020 |
Why?
|
Thailand | 1 | 2010 | 286 | 0.020 |
Why?
|
Tomography, X-Ray Computed | 1 | 2013 | 20350 | 0.020 |
Why?
|
Community Health Services | 1 | 2014 | 654 | 0.020 |
Why?
|
Computer Simulation | 1 | 2022 | 6176 | 0.020 |
Why?
|
Risk | 1 | 2021 | 9613 | 0.020 |
Why?
|
Hospitalization | 1 | 2008 | 10628 | 0.020 |
Why?
|
Condoms | 1 | 2010 | 310 | 0.020 |
Why?
|
Population Dynamics | 1 | 2010 | 302 | 0.020 |
Why?
|
Point-of-Care Systems | 1 | 2017 | 1185 | 0.020 |
Why?
|
Feasibility Studies | 1 | 2018 | 5144 | 0.020 |
Why?
|
Registries | 1 | 2022 | 8363 | 0.020 |
Why?
|
Lipids | 1 | 2017 | 3325 | 0.020 |
Why?
|
Substance Abuse, Intravenous | 1 | 2010 | 530 | 0.020 |
Why?
|
Lung | 1 | 2024 | 9899 | 0.020 |
Why?
|
Clinical Trials as Topic | 1 | 2021 | 7997 | 0.020 |
Why?
|
Patient Compliance | 1 | 2014 | 2680 | 0.010 |
Why?
|
Health Status | 1 | 2017 | 4050 | 0.010 |
Why?
|
Primary Health Care | 1 | 2020 | 4617 | 0.010 |
Why?
|
Healthcare Disparities | 1 | 2019 | 3302 | 0.010 |
Why?
|
Health Behavior | 1 | 2014 | 2614 | 0.010 |
Why?
|
Pandemics | 1 | 2022 | 8499 | 0.010 |
Why?
|
Homosexuality, Male | 1 | 2010 | 1253 | 0.010 |
Why?
|
Cholesterol, LDL | 1 | 2010 | 2407 | 0.010 |
Why?
|
Infant | 1 | 2022 | 35673 | 0.010 |
Why?
|
Emergency Service, Hospital | 1 | 2018 | 7730 | 0.010 |
Why?
|
Algorithms | 1 | 2018 | 13905 | 0.010 |
Why?
|
Models, Statistical | 1 | 2011 | 5053 | 0.010 |
Why?
|
Breast Neoplasms | 1 | 2021 | 20844 | 0.010 |
Why?
|
Treatment Outcome | 1 | 2019 | 64288 | 0.010 |
Why?
|